Related Experiment Video
Updated: Jul 8, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients
Macaulay A C Onuigbo1, Nnonyelum T C Onuigbo
1Mayo Clinic College of Medicine, Rochester, MN, USA. onuigbo.macaulay@mayo.edu
Insights
Discontinuing renin-angiotensin-aldosterone blockade (AB) in patients with chronic kidney disease (CKD) can improve estimated glomerular filtration rate (eGFR), even without traditional risk factors. This intervention may help mitigate iatrogenic kidney injury and slow CKD progression.
Area of Science:
- Nephrology
- Internal Medicine
- Pharmacology
Background:
- Renin-angiotensin-aldosterone blockade (AB) is widely used for cardiovascular protection but may contribute to chronic kidney disease (CKD) and end-stage renal disease (ESRD) in susceptible individuals.
- Despite proven benefits, a CKD/ESRD epidemic persists, raising concerns about iatrogenic kidney injury from AB.
- This study investigated the impact of AB withdrawal on estimated glomerular filtration rate (eGFR) in CKD patients.
Observation:
- A prospective study enrolled 100 CKD patients experiencing a >25% increase in serum creatinine while on AB.
- Patients were monitored for changes in serum creatinine, MDRD eGFR, and urine albumin-to-creatinine ratio (UA/Cr) after AB withdrawal.
- The cohort had a mean age of 71.5 years, and follow-up averaged 26 months.
Findings:
- Discontinuation of AB led to a significant improvement in eGFR in 74% of patients, from 23.9 to 39.2 ml/min/1.73 m² (P=0.001).
- While 16 patients progressed to ESRD (seven died), 95 had known risk factors like renal artery stenosis (RAS) or NSAID use.
- Five patients without traditional risk factors showed sustained eGFR improvement after stopping or reducing AB.
Implications:
- Worsening azotemia in CKD patients on AB, sometimes without clear precipitating factors, is under-recognized.
- Discontinuing AB can lead to sustained eGFR improvement, suggesting a role in managing iatrogenic kidney injury.
- Physicians should consider AB withdrawal in susceptible CKD patients presenting with worsening renal function.
Introduction:
Notwithstanding proven renoprotection from RAAS blockade (AB) with ACE inhibitors and ARBs, and despite increasing utilization of AB in the US, we have continued to experience a CKD/ESRD epidemic. Given concerns for iatrogenic CKD/ESRD, we designed a prospective study to analyze the course of eGFR following withdrawal of AB in such patients.
Patients:
Between September 2002 and February 2005, all consecutive CKD patients on AB presenting with >25% increase in baseline serum creatinine were enrolled. eGFR following withdrawal of AB was monitored. The main outcome measures were serum creatinine, MDRD eGFR, and UA/Cr.
Results:
100 Caucasians, M:F=52:48, mean age 71.5 years were enrolled. Mean follow up was 26 months. Sixteen patients progressed to ESRD, of whom seven died. In 74, eGFR improved from 23.9+/-9 (7-47) to 39.2+/-15.4 (17-89) ml/min/1.73 m(2) BSA, 26.5 (3-46) months after stopping AB (P=0.001). The majority of the cohort, 95 patients, had known risk factors: 26 with RAS, 12 hypovolemia, 11 sepsis, 10 NSAIDs/cox II inhibitor use/abuse, 7 CIN, 2 congestive heart failure, 2 obstructive uropathy, and 27 with other medical and surgical causes, including malignancies, postoperative states, and infections. In the 26 with RAS, 5 with higher baseline creatinine -2.1+/-0.6 versus 1.5+/-0.4 mg/dL, P=0.013, progressed to ESRD; 4/5 ESRD patients died after 6.3 months. The remaining five patients (one male and four females), mean age 68 (44-83) years, demonstrated sustained improved eGFR with discontinuation (four) or reduction (one) of RAAS blockade, despite normal renal arteries and the absence of known traditional risk factors. UA/Cr generally increased following withdrawal of AB.
Conclusions:
Worsening azotemia in older susceptible CKD patients on AB, often but not always associated with known precipitating risk factors, remains under-recognized. Sustained improved eGFR often follows the discontinuation of AB. The practising physician should be well aware of these syndromes. Our observations call for further study.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
